iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.28 Billion KRW | -115.69% |
| 2022 | -1.52 Billion KRW | -115.8% |
| 2021 | 9.63 Billion KRW | -36.81% |
| 2020 | 15.25 Billion KRW | 391.85% |
| 2019 | -5.22 Billion KRW | -266.97% |
| 2018 | 3.12 Billion KRW | 155.15% |
| 2017 | -5.67 Billion KRW | -372.75% |
| 2016 | -1.2 Billion KRW | -156.31% |
| 2015 | 2.13 Billion KRW | 0.0% |
| 2012 | -1.11 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.11 Billion KRW | -624.58% |
| 2024 Q2 | -1.15 Billion KRW | -3.85% |
| 2023 FY | -3.28 Billion KRW | -115.69% |
| 2023 Q3 | -733.48 Million KRW | 28.5% |
| 2023 Q4 | -153.29 Million KRW | 79.1% |
| 2023 Q2 | -1.02 Billion KRW | 25.24% |
| 2023 Q1 | -1.37 Billion KRW | -22.9% |
| 2022 Q3 | -462.3 Million KRW | 69.55% |
| 2022 FY | -1.52 Billion KRW | -115.8% |
| 2022 Q4 | -1.11 Billion KRW | -141.51% |
| 2022 Q2 | -1.51 Billion KRW | -196.45% |
| 2022 Q1 | 1.57 Billion KRW | -59.89% |
| 2021 Q1 | 1.51 Billion KRW | -64.53% |
| 2021 FY | 9.63 Billion KRW | -36.81% |
| 2021 Q4 | 3.92 Billion KRW | 118.99% |
| 2021 Q2 | 2.51 Billion KRW | 66.26% |
| 2021 Q3 | 1.79 Billion KRW | -28.67% |
| 2020 Q3 | 816.24 Million KRW | -92.94% |
| 2020 FY | 15.25 Billion KRW | 391.85% |
| 2020 Q4 | 4.25 Billion KRW | 421.79% |
| 2020 Q1 | -902.46 Million KRW | 21.66% |
| 2020 Q2 | 11.56 Billion KRW | 1381.31% |
| 2019 FY | -5.22 Billion KRW | -266.97% |
| 2019 Q4 | -1.15 Billion KRW | 10.82% |
| 2019 Q3 | -1.29 Billion KRW | -45.88% |
| 2019 Q2 | -885.46 Million KRW | 14.77% |
| 2019 Q1 | -1.03 Billion KRW | -111.39% |
| 2018 FY | 3.12 Billion KRW | 155.15% |
| 2018 Q2 | -929.54 Million KRW | 18.42% |
| 2018 Q1 | -1.13 Billion KRW | 3.31% |
| 2018 Q3 | -1.89 Billion KRW | -103.38% |
| 2018 Q4 | 9.12 Billion KRW | 582.69% |
| 2017 Q1 | -814.08 Million KRW | 68.24% |
| 2017 FY | -5.67 Billion KRW | -372.75% |
| 2017 Q4 | -1.17 Billion KRW | 6.05% |
| 2017 Q3 | -1.25 Billion KRW | -91.85% |
| 2017 Q2 | -653.71 Million KRW | 19.7% |
| 2016 FY | -1.2 Billion KRW | -156.31% |
| 2016 Q4 | -2.56 Billion KRW | -481.84% |
| 2016 Q3 | -440.58 Million KRW | -133.86% |
| 2016 Q2 | -188.39 Million KRW | -4.23% |
| 2016 Q1 | -180.74 Million KRW | 0.0% |
| 2015 FY | 2.13 Billion KRW | 0.0% |
| 2013 Q3 | 2.46 Million KRW | -19.61% |
| 2013 Q2 | 3.06 Million KRW | -98.37% |
| 2013 Q1 | 187.84 Million KRW | 149.32% |
| 2012 FY | -1.11 Billion KRW | 0.0% |
| 2012 Q4 | -380.88 Million KRW | -69.53% |
| 2012 Q3 | -224.67 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 97.373% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 415.176% |
| Bioneer Corporation | 791.75 Million KRW | 514.897% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 35.257% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 86.928% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 89.374% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 90.68% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 65.147% |
| Medy-Tox Inc. | 17.32 Billion KRW | 118.964% |
| Peptron, Inc. | -15.6 Billion KRW | 78.947% |
| Amicogen, Inc. | 2.05 Billion KRW | 259.763% |
| Genexine, Inc. | -41.24 Billion KRW | 92.035% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 62.243% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 95.936% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 66.263% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 103.258% |
| SillaJen, Inc. | -21.34 Billion KRW | 84.611% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 224.731% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 81.936% |
| Genomictree Inc. | -17.3 Billion KRW | 81.016% |
| MedPacto, Inc. | -28.75 Billion KRW | 88.575% |
| D&D Pharmatech | -13.48 Billion KRW | 75.642% |
| EASY BIO,Inc. | 20.63 Billion KRW | 115.922% |
| GI Innovation, Inc. | -55.6 Billion KRW | 94.092% |